PubRank

Gamal Akabani

Author PubWeight™ 19.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003 1.63
2 MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010 1.61
3 Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 2008 1.59
4 Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2007 1.57
5 Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002 1.32
6 Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006 1.12
7 Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 2006 1.06
8 An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J Gene Med 2004 1.00
9 A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 2008 0.99
10 Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT. Radiology 2007 0.91
11 Radioimmunotherapy for Non-Hodgkin's Lymphoma. Clin Med Res 2005 0.91
12 In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. J Nucl Med 2003 0.85
13 The role of cAMP-dependent signaling in receptor-recognized forms of alpha 2-macroglobulin-induced cellular proliferation. J Biol Chem 2002 0.83
14 Comparative dosimetry of BEIR VI revisited. Radiat Prot Dosimetry 2004 0.83
15 Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med 2006 0.82
16 Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 2004 0.82
17 Feasibility of whole-body functional mouse imaging using helical pinhole SPECT. Mol Imaging Biol 2009 0.80
18 Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol 2007 0.78
19 Preliminary production of 211At at the Texas A&M University Cyclotron Institute. Health Phys 2014 0.75
20 Radiological safety concerns for the accelerator production of diagnostic and therapeutic radionuclides in a university setting. Health Phys 2012 0.75